Companies / Health Care / Biotechnology
Vertex Pharmaceuticals stock buybacks
VRTX$2.0Bbought back in the 12 months to Jun 30, 2026
Vertex Pharmaceuticals bought back $2.0B of its stock in the last twelve months, $1.3B more than it paid out in stock compensation. Its share count is down 1.4% from a year earlier.
Show as table
| Period | Value |
|---|---|
| Q3 '20 | $108.0M |
| Q4 '20 | $131.1M |
| Q1 '21 | $424.9M |
| Q2 '21 | $0 |
| Q3 '21 | $632.3M |
| Q4 '21 | $368.2M |
| Q1 '22 | $0 |
| Q2 '22 | $0 |
| Q3 '22 | $0 |
| Q4 '22 | $0 |
| Q1 '23 | $132.8M |
| Q2 '23 | $28.3M |
| Q3 '23 | $117M |
| Q4 '23 | $149.5M |
| Q1 '24 | $131.2M |
| Q2 '24 | $320.3M |
| Q3 '24 | $307.7M |
| Q4 '24 | $417.9M |
| Q1 '25 | $426.1M |
| Q2 '25 | $391.8M |
| Q3 '25 | $1.1B |
| Q4 '25 | $128.4M |
| Q1 '26 | $336.9M |
| Q2 '26 | $469.5M |
Show as table
| Period | Value |
|---|---|
| Q3 '20 | 264.1M |
| Q4 '20 | 263.1M |
| Q1 '21 | 261.9M |
| Q2 '21 | 261.0M |
| Q3 '21 | 259.7M |
| Q4 '21 | 257.0M |
| Q1 '22 | 257.9M |
| Q2 '22 | 258.7M |
| Q3 '22 | 259.5M |
| Q4 '22 | 260.3M |
| Q1 '23 | 260.3M |
| Q2 '23 | 260.4M |
| Q3 '23 | 260.6M |
| Q4 '23 | 260.7M |
| Q1 '24 | 261.1M |
| Q2 '24 | 258.1M |
| Q3 '24 | 261.0M |
| Q4 '24 | 251.4M |
| Q1 '25 | 259.5M |
| Q2 '25 | 258.9M |
| Q3 '25 | 257.6M |
| Q4 '25 | 256.0M |
| Q1 '26 | 256.3M |
| Q2 '26 | 255.2M |
$470Mlast quarter (Q2 2026)
$1.3Bnet of stock compensation ($689M)
−1.4%diluted shares, 1 year
−2.1%diluted shares, 5 years
—dividends, 12 months
53%of free cash flow ($3.8B) spent on buybacks
$0raised by issuing stock, 12 months
$2.6Bleft under its authorization as of Jun 30, 2026
By fiscal year
Questions
- Does Vertex Pharmaceuticals buy back its stock?
- Vertex Pharmaceuticals bought back $2.0B of its stock in the last twelve months, $1.3B more than it paid out in stock compensation. Its share count is down 1.4% from a year earlier.
- How much did Vertex Pharmaceuticals spend on buybacks in fiscal 2025?
- $2.0B, according to its 10-K for the fiscal year ending Dec 31, 2025.
- Is Vertex Pharmaceuticals's share count going down?
- Its diluted share count changed −2.1% over five fiscal years and −1.4% over the last year.
- Does Vertex Pharmaceuticals have a buyback authorization?
- Its filings show $2.6B remaining under its repurchase authorization as of Jun 30, 2026.
Latest filing used: 10-Q for the period ending Jun 30, 2026, filed Aug 4, 2026 · open on SEC.gov